Peptide library / Immune & defense / Murepavadin
Murepavadin
A first-in-class peptide antibiotic targeting Pseudomonas aeruginosa.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Pseudomonas lung infectionsSmall human studies
How it is thought to work
Murepavadin blocks LptD, a protein Pseudomonas needs to build its outer membrane.
What the evidence shows
Intravenous phase 3 trials were stopped because of kidney injury. An inhaled version is being studied.
Safety and unknowns
Kidney toxicity halted the intravenous program.
Regulatory status
Not approved.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Nangibotide
In clinical trialsA TREM-1 inhibitor peptide tested in septic shock.
Oritavancin
FDA-approvedA long-acting lipoglycopeptide antibiotic given as a single infusion.
LTX-315
In clinical trialsAn oncolytic peptide injected into tumors to trigger an immune attack.
General information, not medical advice. Do not buy or inject unregulated peptides.